This proposed research has two major goals: I. to improve identification of drug abuse in diverse populations, so as to aid in more appropriately specialized treatment planning; and 2. to improve evaluation of drug abuse treatment efficacy with patients differing in co-occurring psychiatric disorders, and differing in gender and ethnicity. Concluding that assessment of drug abuse as a discrete diagnosable disorder belies significant obstacles to reliable and valid identification and treatment, this proposal seeks to produce a differentiated family of scales of identify drug abuse among dually diagnosed individuals (i.e., those with co-occurring serious mental illness) with and without a co-morbid Post- traumatic Stress Disorder (PTSD). This research build upon a formidable base: The newly-revised and renormed MMPI-2 will be used to empirically derive scales to measure presence/absence of drug abuse in the context of (a) presence/absence of co-morbid PTSD; (b)presence/absence of other Axis disorders, such as schizophrenia or major mood disorder; (c) gender; and (d) ethnicity (white/minority). At least 480 treatment-seeking individuals with be diagnosed using CAMMI guidelines (Comprehensive Assessment Multimethod, Multisource Information) for research diagnosis, to yield 15 subjects in 32 cells (drug abuse status x PTSD x co-occurring Axis I status X Gender X Ethnicity). With CAMMI-derived Index diagnoses, MMPI-2 drug abuse scales are then differentiated, based on criterion group distinction methods. The results will enhance efficacy of drug abuse treatment in three ways: l. through more valid, more refined identification of individuals with drug abuse; 2. through provision of an empirical base for assigning individual to more specialized drug abuse treatment programs; and 3. through development of MMPI-2 scales sensitive to variations in treatment, gender, and ethnicity. Revision of the MMPI-2 render it an especially attractive assessment tool, particularly for """"""""matching"""""""" studies and measures of treatment process and outcome.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA008415-02
Application #
2120908
Study Section
Drug Abuse Epidemiology and Prevention Research Review Committee (DAPA)
Project Start
1994-09-30
Project End
1997-08-31
Budget Start
1995-09-01
Budget End
1996-08-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Massachusetts Boston
Department
Administration
Type
Other Domestic Higher Education
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02125